Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 10

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Plasma cell myeloma

Recruiting

Study of ciltacabtagene autoleucel in patients with newly diagnosed multiple myeloma using a modified treatment preparation regimen

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ciltacabtagene Autoleucel
  • Sponsor:Janssen Cilag International

B-cell lymphoma+2

Recruiting

Study of LUMC-BOB1-B7-TCR.

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:LUMC-BOB1-B7-TCR.1
  • Sponsor:Leiden University Medical Center

Asplenia

Recruiting

Study of Pneumococcal Vaccine Response in Patients Without a Spleen: Comparing Vaccination Before and After Spleen Removal Using PCV20 and PCV21

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
  • Sponsor:Leiden University Medical Center

Mantle cell lymphoma

Recruiting

Study of Glofitamab and Pirtobrutinib Treatment in Patients with Mantle Cell Lymphoma Who Have Failed Previous Therapy and in Previously Untreated Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Klinikum der Universitaet Muenchen AöR

Acute myeloid leukaemia+3

Recruiting

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Medizinische Hochschule Hannover

Plasma cell myeloma

Recruiting

Study of etentamig and iberdomide treatment for patients with relapsed or refractory multiple myeloma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Etentamig
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Acute lymphocytic leukaemia+1

Recruiting

Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Ascentage Pharma Group Inc.

B-cell lymphoma recurrent+1

Recruiting

Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Diffuse large B-cell lymphoma+2

Recruiting

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaet Muenster

Hodgkin's disease

Recruiting

Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:University Of Cologne

Immune thrombocytopenia

Recruiting

Study of NVG-2089 given by intravenous infusion in patients with immune thrombocytopenia to evaluate safety and effectiveness

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:NVG-2089
  • Sponsor:Nuvig Therapeutics Inc.

T-cell type acute leukaemia+2

Recruiting

Study of CART84 Treatment for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Gyala Therapeutics S.L.

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.